Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ajey Alurkar (NPI 1043431026)

Field	Value
Entity Type	Individual
Organization	Ajey Alurkar
Address	210 N State St Ste 1&5
City	Clarks Summit
State	PA
ZIP	18411
Taxonomy	Ophthalmology Physician
NPI Enumerated	May 1, 2007

Payer Source	Total Paid
Medicare	$4.1M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in scope: lifetime Medicare revenue is $4.1M and there is no Medicaid billing on file. The absence of Medicaid activity indicates minimal exposure to state program reimbursement and a heavy dependence on Medicare for top-line volume. This concentration should be considered when modeling payer-mix sensitivity and contract negotiations.

Revenue is highly concentrated in a small set of injection and procedure codes: the precomputed top 3 Medicare codes account for 84.3% of total Medicare revenue, with J0178 alone generating $3M (74.0% of Medicare revenue). That concentration means changes in reimbursement or utilization for a single drug/procedure could materially affect this provider’s revenue.

The code mix and volumes point to a retina-focused ophthalmology practice operating a high-throughput intravitreal injection clinic: high-volume drug codes J0178 (4.4K claims, $689 avg paid/claim) and J2777 (8K claims, $29 avg paid/claim) plus injection procedure 67028 (2.1K claims, $89 avg paid/claim) together drive the bulk of revenue. Supporting services such as retinal imaging (92134, 2K claims) and fundus photography (92250, 1K claims) are also present, consistent with ongoing medical retina management rather than primarily cataract surgery.

Competitive standing for the top drug is nationally prominent: J0178 ranks #45 of 3204 providers nationally and is labeled an "extreme outlier," indicating this provider bills far above typical national volume for aflibercept. By contrast, other high‑use codes show mixed competitive positions—67028 ranks high (91th percentile) indicating above‑typical procedural volume, while J2777 sits at a more typical level (42th percentile). This pattern suggests national leadership specifically in aflibercept administration while other services are above‑average or typical.

Several non‑drug codes also show unusually high relative volumes, signaling broad retina service capacity: 92134 (retinal OCT) ranks in the 96th percentile and is described as "notably above typical," 92012 (established intermediate exam) is in the 96th percentile and likewise described as "notably above typical," and 92250 (fundus photos) is an "extreme outlier" at the national level. High relative volumes for diagnostic imaging and office exams imply repeat follow-up and monitoring consistent with chronic retina disease management.

Operational implications from claim counts are material: 4.4K claims for J0178 and 2.1K claims for 67028 indicate sustained procedural throughput, while 8K claims for J2777 (despite lower average payment per claim) suggest frequent utilization of that injectable product. These volumes imply dedicated staffing, inventory, and billing workflows focused on intravitreal therapies and associated diagnostics, which are critical levers for cost and quality management.

Tenure is long and may support established referral relationships: the NPI was enumerated on 2007-05-01 (~19 years ago), indicating a stable presence in CLARKS SUMMIT, PA. That longevity combined with high procedure volumes for retina services suggests entrenched clinical operations and referral patterns in the local market.

From a payer contracting and risk perspective, the practice’s heavy Medicare weighting and drug‑centric revenue profile create both negotiating leverage and vulnerability: leverage comes from being a top national outlier on J0178 ($3M), but vulnerability arises from the lack of Medicaid diversification (none on file) and the fact that a single drug/procedure cluster represents the majority of revenue. Payors modeling utilization changes or shifts in drug selection should flag this provider for targeted review and for potential inclusion in specialty drug management or value‑based arrangements.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	4,380	$690	$3M
J2777	Injection, faricimab‑svoa, 0.1 mg	8,040	$30	$233.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,060	$90	$183.5K
J3490	Unclassified drugs	70	$1,760	$114.6K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	890	$120	$106.2K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	480	$160	$74.3K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,960	$30	$54.7K
66821	The provider removes the haziness from the capsule of the eye using a laser for a patient with a secondary membranous cataract.	180	$300	$52.5K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	830	$60	$52K
J2778	Injection, ranibizumab, 0.1 mg	240	$180	$42.1K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Ajey Alurkar — 5 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	5	140	830	$690	$865.1K
J2778	61	70	1,030	$190	$417.1K
J2777	47	100	7,950	$30	$360.2K
J2781	8	20	690	$120	$109.1K
67028	27	180	600	$90	$87.5K
J7312	2	10	280	$160	$50.7K
J7999	105	110	100	$120	$33.3K
J3490	50	110	60	$70	$27.9K
92014	308	1,570	130	$80	$21K
66821	41	420	50	$230	$18.3K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ajey Alurkar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alexander Bottini	GA	Retina Specialist (Ophthalmology) Physician	$3M	$0
Vatsal Doshi	NJ	Retina Specialist (Ophthalmology) Physician	$2.2M	$130
Sana Idrees	NY	Retina Specialist (Ophthalmology) Physician	$1.7M	$1.6K
Chirag Patel	NJ	Ophthalmology Physician	$1.5M	$0
Kartik Patel	NJ	Ophthalmology Physician	$1.4M	$0
Konstantin Astafurov	NJ	Retina Specialist (Ophthalmology) Physician	$1.2M	$0
Boleslav Kotlyar	NJ	Retina Specialist (Ophthalmology) Physician	$958.1K	$0
Joseph Raevis	NJ	Ophthalmology Physician	$874.9K	$500
Patrick Coady	NJ	Ophthalmology Physician	$728.9K	$0
Arkadiy Yadgarov	GA	Glaucoma Specialist (Ophthalmology) Physician	$561.8K	$0

Nearby Providers

Other providers in the same ZIP code as Ajey Alurkar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Caregivers America Home Health Services, LLC.	PA	Home Health Agency	$0	$36.7M
Caregivers America LLC	PA	Home Health Aide	$0	$31.9M
Bayada Home Health Care, Inc.	PA	Home Health Agency	$0	$11.3M
Northeast Dermatopathology Institute	PA	Clinical Medical Laboratory	$569.8K	$4.1K
Samir Pancholy	PA	Interventional Cardiology Physician	$485.6K	$0
Haitham Abughnia	PA	Internal Medicine Physician	$439.5K	$0
Stephen Sorokanich	PA	Ophthalmology Physician	$319.3K	$0
Barbara Plucknett	PA	Gynecology Physician	$185.4K	$0
Eric Smith	PA	Internal Medicine Physician	$131.4K	$0
Sheela Prahalad	PA	Internal Medicine Physician	$129.3K	$0

Ajey Alurkar — Billing Profile & Reimbursement Data

Sign up for Ajey Alurkar — Billing Profile & Reimbursement Data policy alerts

Ajey Alurkar — Billing Profile & Reimbursement Data

Sign up for Ajey Alurkar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References